Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Tedesco, K L

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar 2004 - 1071-7 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

0732-183X

10.1200/JCO.2004.10.046 doi


Adult
Aged
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Breast Neoplasms--drug therapy
Disease-Free Survival
Docetaxel
Female
Gene Expression Regulation, Neoplastic
Humans
In Situ Hybridization, Fluorescence
Middle Aged
Receptor, ErbB-2--antagonists & inhibitors
Receptor, ErbB-3--antagonists & inhibitors
Survival Analysis
Taxoids--administration & dosage
Trastuzumab
United States
Up-Regulation